Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 668.00
Change Today -0.20 / -0.03%
Volume 49.0K
As of 3:48 AM 07/5/15 All times are local (Market data is delayed by at least 15 minutes).

redhill biopharma ltd (RDHL) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/15/15 - $910.10
52 Week Low
11/18/14 - $295.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for REDHILL BIOPHARMA LTD (RDHL)

Related News

No related news articles were found.

redhill biopharma ltd (RDHL) Related Businessweek News

No Related Businessweek News Found

redhill biopharma ltd (RDHL) Details

RedHill Biopharma Ltd., a biopharmaceutical company, focuses on the development and acquisition of late clinical-stage, proprietary, and orally-administered drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers in Israel. The company’s pipeline of therapeutic candidates include RHB-105, which is in Phase III clinical trial, intended for the eradication of Helicobacter pylori infection; and RHB-104 that is in Phase III clinical trial for the treatment of Crohn's disease, in Phase IIa proof of concept clinical trial for the treatment of multiple sclerosis, and under pre-clinical studies for the treatment of rheumatoid arthritis. Its pipeline of therapeutic candidates also comprise BEKINDA, which is under review with FDA, for the prevention of chemotherapy and radiotherapy induced nausea and vomiting, and in Phase III clinical trial for the treatment of gastroenteritis and gastritis; and RHB-106 intended for the preparation and cleansing of the gastrointestinal tract prior to the performance of abdominal procedures. In addition, the company’s pipeline of therapeutic candidates consist of MESUPRON, a urokinase-type plasminogen activator inhibitor targeting gastrointestinal and other solid tumor cancers, which has completed various Phase I clinical trials and two Phase II proof of concept clinical trials; RP101, a heat shock protein 27 inhibitor for the treatment of pancreatic and other gastrointestinal cancers, which has completed various Phase I and Phase II clinical trials; RIZAPORT, an oral thin film formulation of rizatriptan for acute migraines; and RHB-101 for the treatment of hypertension, heart failure, and left ventricular dysfunction. Further, its pipeline of proprietary products comprises ABC294640, a Phase II-stage orally-administered sphingosine kinase-2 inhibitor targeting various inflammatory, gastrointestinal, and oncology indications. The company was founded in 2009 and is based in Tel Aviv, Israel.

10 Employees
Last Reported Date: 02/26/15
Founded in 2009

redhill biopharma ltd (RDHL) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $280.2K
Deputy Chief Executive Officer of Finance & O...
Total Annual Compensation: $237.6K
Senior Vice President of Research & Developme...
Total Annual Compensation: $233.2K
Senior Vice President of Corporate & Product ...
Total Annual Compensation: $216.0K
Chief Business Officer
Total Annual Compensation: $199.3K
Compensation as of Fiscal Year 2014.

redhill biopharma ltd (RDHL) Key Developments

Redhill Biopharma Initiates Phase I/II Study of ABC294640 for Refractory Lymphoma

RedHill Biopharma Ltd. announced that it has initiated a Phase I/II clinical study in the U.S. evaluating ABC294640 in patients with refractory/relapsed diffuse large B-cell lymphoma (DLBCL). ABC294640 is a proprietary, first-in-class, orally-administered sphingosine kinase-2 (SK2) selective inhibitor, with anti-inflammatory and anti-cancer activities, targeting multiple inflammatory, gastrointestinal (GI) and oncology indications. SK2 is an innovative molecular target for anti-cancer therapy because of its critical role in catalyzing the formation of the lipid-signaling molecule sphingosine 1-phosphate (S1P), which is known to regulate cell proliferation and activation of inflammatory pathways. By inhibiting SK2, ABC294640 could potentially be effective in treating multiple inflammatory, oncologic and gastrointestinal diseases. The Phase I/II study is intended to evaluate the safety and tolerability of ABC294640, as well as provide a preliminary evaluation of efficacy of the drug in patients with refractory/relapsed DLBCL, primarily patients with HIV-related DLBCL. Up to 33 patients are expected to be enrolled in the study, which will be conducted at the Louisiana State University Health Sciences Center (LSUHSC) in New Orleans. The study is funded primarily by a grant awarded by the National Cancer Institute (NCI) Small Business Technology Transfer (STTR) program. The Phase I/II study was initiated following positive pre-clinical studies, led by Dr. Parsons, indicating the therapeutic activity of ABC294640 for virus-associated DLBCL, in an established xenograft model for Kaposi's sarcoma-associated herpesvirus-associated DLBCL, including reversal of disease progression for established tumors. The pre-clinical studies were performed in parallel with a successful Phase I study that demonstrated the drug's safety and assessed its pharmacokinetics and pharmacodynamics in cancer patients with advanced solid tumors.

UK MHRA Accepts Redhill's Clinical Trial Application to Initiate Second Phase III Study of RHB-104 for Crohn's Disease

RedHill Biopharma Ltd. announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted RedHill's Clinical Trial Application (CTA) to initiate a second Phase III study of RHB-104 for Crohn's disease (the MAP EU study). The MAP EU study is planned to commence in a selected number of European counties, and, once initiated, will run in parallel with the currently ongoing MAP US first Phase III study. RHB-104 is a proprietary and potentially groundbreaking antibiotic combination therapy in oral capsule formulation, with potent intracellular, anti-mycobacterial and anti-inflammatory properties. The randomized, double-blind, placebo-controlled MAP EU Phase III study is expected to enroll 360 patients with moderately active Crohn's disease. Patients will be randomized 2:1 to receive either RHB-104 or a placebo for 52 weeks, and then evaluated for remission at week 26 as the primary endpoint. In addition, RHB-104 is currently undergoing a first Phase III study in the U.S., Canada, Israel, Australia, New Zealand and Europe (the MAP US study). The ongoing randomized, double-blind, placebo-controlled MAP US Phase III study is expected to enroll 270 patients with moderately to severely active Crohn's disease. Patients are randomized 1:1 to receive either RHB-104 or a placebo for 52 weeks, and are then evaluated for the primary endpoint of remission at week 26 of treatment. Interim analysis of the MAP US study is expected in the second half of 2016, after half of the patients expected to be enrolled in the study will have completed 26 weeks of treatment.

RedHill Biopharma Ltd. - Special Call

To discuss positive top-line results from its Phase III study with RHB-105 for the treatment of Helicobacter pylori (H. pylori) bacterial infection


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RDHL:IT 668.00 -0.20

RDHL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RDHL.
View Industry Companies

Industry Analysis


Industry Average

Valuation RDHL Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REDHILL BIOPHARMA LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at